NASDAQ:VKTX的维京治疗公司在周三收盘后公布了其第四季度财务业绩。以下是报告中的详细信息。
维京治疗公司报告季度每股亏损32美分，未达到分析师预期的每股亏损28美分。去年同期公司每股亏损为25美分。
维京报告称，第四季度净亏损为3540万美元，而2023年同期的净亏损为2460万美元。
截至2024年12月31日的一年中，研究与开发费用为1.016亿美元，而2023年同期为6380万美元。这一增长主要是由于药物候选产品的制造费用、基于股票的补偿和工资福利增加，部分被临床和临床前研究费用的减少所抵消。
维京首席执行官Brian Lian博士表示：“2024年是维京激动人心且极具成效的一年。公司在四个不同的临床试验中报告了积极数据，包括用于肥胖的皮下注射VK2735的二期VENTURE研究、用于肥胖的口服VK2735的一期研究、用于治疗MASH和纤维化的VK2809的二期VOYAGE研究以及用于X-ALD的VK0214的一期研究。每个研究都成功达到了其目标，并在我们看来展示了同类中最好的数据。”
根据Benzinga Pro的数据，维京治疗公司股价在周三盘后下跌8.72%，至每股30.58美元。
图片来源：T. Schneider via Shutterstock
以上内容来自Benzinga Earnings专栏，原文如下：
Viking Therapeutics, Inc. (NASDAQ:VKTX) annnounced its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the details from the report.
The Details: Viking Therapeutics reported quarterly losses of 32 cents per share, which missed the analyst consensus estimate for losses of 28 cents. The company reported losses of 25 cents per share in the same period last year.
Viking reported a net loss of $35.4 million in the fourth quarter, compared to a net loss of $24.6 million, in the corresponding period in 2023.
Research and development expenses for the year ended Dec. 31, 2024, were $101.6 million compared to $63.8 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for drug candidates, stock-based compensation and salaries and benefits, partially offset by a decrease in expenses related to clinical studies and preclinical studies.
Read Next: Ford Shares Skid After Q4 Report: Details
“2024 was an exciting and extremely productive year for Viking,” stated Brian Lian, Ph.D., CEO of Viking.
“During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for the treatment of MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD. Each of these studies successfully achieved their objectives with each in our view demonstrating best-in-class data,” Lian said.
VKTX Price Action: According to data from Benzinga Pro, Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday.
Read Next:
Photo: T. Schneider via Shutterstock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.